Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

XOMA Royalty Corporation - Common Stock (NQ:XOMA)

25.52 -0.54 (-2.07%)
Streaming Delayed Price Updated: 10:37 AM EST, Dec 29, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 125,826
Open 26.01
Bid (Size) 25.29 (100)
Ask (Size) 26.33 (100)
Prev. Close 26.06
Today's Range 25.52 - 26.57
52wk Range 18.35 - 39.92
Shares Outstanding 11,782,723
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
XOMA Royalty Declares Quarterly Preferred Stock Dividends
From XOMA Royalty Corporation
Via GlobeNewswire
News headline image
XOMA Royalty Enters into Agreement to Acquire Generation Bio
From Generation Bio Co.; XOMA Royalty Corporation
Via GlobeNewswire

Performance

YTD
-1.8%
-1.8%
1 Month
-20.6%
-20.6%
3 Month
-31.4%
-31.4%
6 Month
+1.3%
+1.3%
1 Year
-2.2%
-2.2%

More News

Read More
News headline image
XOMA Royalty Corporation: A Deep Dive into a Biotech Royalty Aggregator (12/13/2025)
Via PredictStreet
Topics Intellectual Property
LAVA Therapeutics Stock Slips 9% Pre-Market – Here’s Why The Company Canceled Its Shareholder Meeting ↗
Via Stocktwits
Mural Oncology To Be Acquired By Xoma Royalty ↗
Via Stocktwits
News headline image
XOMA Royalty Announces Closing of Transaction to Acquire Mural Oncology plc
From XOMA Royalty Corporation
Via GlobeNewswire
News headline image
Mural Oncology Announces Effectiveness of Scheme of Arrangement and Completion of Acquisition
From Mural Oncology plc
Via GlobeNewswire
News headline image
Mural Oncology Announces Final Cash Consideration Payable on Closing of Acquisition by XOMA Royalty
From Mural Oncology plc
Via GlobeNewswire
News headline image
XOMA Royalty Announces Closing of Transactions to Acquire LAVA Therapeutics N.V.
From XOMA Royalty Corporation
Via GlobeNewswire
News headline image
XOMA Royalty Reports Third Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements
From XOMA Royalty Corporation
Via GlobeNewswire
News headline image
Mural Oncology Announces that Mural Shareholders Approve the Proposed Acquisition by XRA 5 Corp., a Wholly Owned Subsidiary of XOMA Royalty
From Mural Oncology plc
Via GlobeNewswire
News headline image
LAVA Therapeutics Stock Drops After Amended Deal With XOMA Royalty ↗
Via Stocktwits
News headline image
XOMA Royalty and LAVA Therapeutics Announce Amendment to Purchase Agreement
From XOMA Royalty Corporation; LAVA Therapeutics N.V.
Via GlobeNewswire
News headline image
Turnstone Biologics: A $100 Dream Collides with a $0.34 Reality
Via MarketMinute
Topics Intellectual Property Workforce
News headline image
XOMA Royalty Extends Tender Offer to Acquire LAVA Therapeutics N.V.
From XOMA Royalty Corporation; LAVA Therapeutics
Via GlobeNewswire
News headline image
XOMA Royalty Declares Quarterly Preferred Stock Dividends
From XOMA Royalty Corporation
Via GlobeNewswire
News headline image
XOMA Royalty Announces Closing of Tender Offer for HilleVax, Inc.
From XOMA Royalty Corporation
Via GlobeNewswire
News headline image
XOMA Royalty to Present at H.C. Wainwright 27th Annual Global Investment Conference
From XOMA Royalty Corporation
Via GlobeNewswire
News headline image
Mural Oncology Announces Entry into Agreement to be Acquired by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty for between $2.035 and $2.24 in Cash per Share
From XOMA Royalty Corporation
Via GlobeNewswire
News headline image
HILLEVAX INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of HilleVax, Inc. - HLVX
From Kahn Swick & Foti, LLC
Via GlobeNewswire
News headline image
XOMA Revenue Jumps 39% in Fiscal Q2 ↗
Via The Motley Fool
News headline image
XOMA Royalty Reports Second Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements
From XOMA Royalty Corporation
Via GlobeNewswire
News headline image
XOMA Royalty Announces Closing of Tender Offer for Turnstone Biologics
From XOMA Royalty Corporation
Via GlobeNewswire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: HilleVax, Inc. (Nasdaq – HLVX), Steelcase Inc. (NYSE – SCS), LAVA Therapeutics N.V. (Nasdaq – LVTX), Arcadia Biosciences, Inc. (Nasdaq – RKDA)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
XOMA Royalty Enters into Agreement to Acquire LAVA Therapeutics for Between $1.16 and $1.24 Per Share in Cash, Plus a Contingent Value Right
From XOMA Royalty Corporation; LAVA Therapeutics N.V.
Via GlobeNewswire

Frequently Asked Questions

Is XOMA Royalty Corporation - Common Stock publicly traded?
Yes, XOMA Royalty Corporation - Common Stock is publicly traded.
What exchange does XOMA Royalty Corporation - Common Stock trade on?
XOMA Royalty Corporation - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for XOMA Royalty Corporation - Common Stock?
The ticker symbol for XOMA Royalty Corporation - Common Stock is XOMA on the Nasdaq Stock Market
What is the current price of XOMA Royalty Corporation - Common Stock?
The current price of XOMA Royalty Corporation - Common Stock is 25.52
When was XOMA Royalty Corporation - Common Stock last traded?
The last trade of XOMA Royalty Corporation - Common Stock was at 12/29/25 10:37 AM ET
What is the market capitalization of XOMA Royalty Corporation - Common Stock?
The market capitalization of XOMA Royalty Corporation - Common Stock is 300.70M
How many shares of XOMA Royalty Corporation - Common Stock are outstanding?
XOMA Royalty Corporation - Common Stock has 301M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.